炎症性肠病患者尿路结石风险:丹麦全国性队列研究1977-2018
该研究利用丹麦全国登记数据,纳入1977-2018年所有炎症性肠病(IBD)患者及尿路结石病例,按年龄和性别1:10匹配非IBD个体。结果显示IBD患者尿路结石风险约增加2倍(HR 2.27,95%CI 2.17-2.38),诊断前风险亦增加(OR 1.42),抗TNF治疗和手术与诊断后风险相关。
要点
- IBD患者尿路结石风险约增2倍(HR 2.27,95%CI 2.17-2.38)。
- IBD诊断前尿路结石风险增加42%(OR 1.42)。
- 抗TNF治疗和手术与IBD诊断后尿路结石风险相关。
核心结论
- IBD患者诊断后尿路结石风险约增2倍,诊断前风险增加42%。
- 抗TNF暴露和手术后风险增加,提示IBD严重程度本身和手术可能增加风险。
- 作者认为,接受强免疫抑制的IBD患者亚群可能从额外尿路结石筛查中获益。
研究设计与样本
- 全国性 population-based 队列研究,利用丹麦国家登记数据1977-2018。
- 共纳入75,236例IBD患者和767,403例非IBD个体,按年龄和性别1:10匹配。
- 获取1995-2018年所有IBD药物和手术信息。
主要发现
- IBD患者中2,549例(3%)发生尿路结石,非IBD个体中11,258例(2%)发生。
- IBD患者尿路结石风险增加2倍(HR 2.27;95%CI 2.17-2.38)。
- IBD患者重复尿路结石事件风险增加(RR 1.09;95%CI 1.04-1.15)。
- IBD诊断前尿路结石风险增加(OR 1.42;95%CI 1.34-1.50)。
- IBD诊断后,尿路结石风险与抗TNF治疗和手术相关。
关键数值与推荐
- IBD患者尿路结石HR 2.27(95%CI 2.17-2.38)。
- 重复尿路结石事件RR 1.09(95%CI 1.04-1.15)。
- 诊断前尿路结石OR 1.42(95%CI 1.34-1.50)。
临床怎么用
- 作者认为,接受强免疫抑制的IBD患者亚群可能从额外尿路结石筛查中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) are suggested to be at increased risk of urolithiasis, but the magnitude of risk and the impact of medical and surgical treatment on this risk remain unknown. We therefore aimed to determine overall and treatment-related risk of urolithiasis in patients with IBD in a nationwide population-based cohort study. METHODS: Using national registers, we identified all patients with IBD and all cases of urolithiasis in Denmark during 1977-2018. We obtained information on all IBD medications and surgical procedures during 1995-2018. IBD cases were matched 1:10 on age and sex to non-IBD individuals. RESULTS: In total, 2,549 (3%) of 75,236 IBD patients and 11,258 (2%) of 767,403 non-IBD individuals developed urolithiasis, resulting in a 2-fold increased risk of urolithiasis (HR, 2.27; 95% CI, 2.17-2.38) in patients with IBD. The patients were also at increased risk of repetitive urolithiasis events (RR, 1.09; 95% CI: 1.04-1.15) and had increased risk of urolithiasis prior to IBD diagnosis (OR, 1.42; 95% CI: 1.34-1.50). After IBD diagnosis, risk of urolithiasis was associated with anti-TNF therapy and surgery. CONCLUSION: Patients with IBD had a 2-fold increased risk of urolithiasis after IBD diagnosis and a 42% increased risk prior to IBD diagnosis. Risk was increased in anti-TNF exposed patients, and after surgery, suggesting that IBD severity per se and surgery, with altered intestinal absorption, increase risk of urolithiasis. Since stone formation is associated with adverse outcomes including sepsis, subpopulations of IBD patients, especially those undergoing strong immunosuppression might benefit from additional urolithiasis screening.
引用
- Dimke H, Winther-Jensen M, Allin KH, et al. Risk of Urolithiasis in Patients With Inflammatory Bowel Disease: A Nationwide Danish Cohort Study 1977-2018. Clin Gastroenterol Hepatol. 2020. PMID: 33007511. doi:10.1016/j.cgh.2020.09.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。